Clik here to view.
Think Equity ups Alnylam price target to $20
Think Equity has raised its price target of “buy-rated” Alnylam Pharmaceuticals (NASDAQ:ALNY) to $20 from $18, by decreasing the discount rate of the company’s two lead proprietary programs, ALN-TTR...
View ArticleClik here to view.
Amorfix lead antibody kills ovarian cancer cells
Amorfix Life Sciences (TSX:AMF) has completed a series of studies with its lead anti-PrP antibody that demonstrate specific, dose-related killing of ovarian tumor cells. The company said the...
View ArticleClik here to view.
Avivagen extends non-surgical sterilization option
Avivagen (TSX-V:VIV) has negotiated a 12-month extension to mid-2016 of its option to a technology for the permanent sterilization of female mammals in order to eliminate the need for surgical spaying....
View ArticleClik here to view.
In conversation with Geoffrey Hamilton-Fairley
Mr. Hamilton-Fairley As CEO of closely-held Oncimmune, an early cancer diagnostic company in Britain, Geoffrey Hamilton-Fairley has had a personal commitment to cancer detection. His father was the...
View ArticleClik here to view.
HCW downgrades CymaBay to neutral
H.C. Wainwright has downgraded CymaBay Therapeutics (NASDAQ:CBAY) to “neutral” from “buy” with a price target of $2.25. The stock closed at $2.44 on Tuesday. Yesterday, CymaBay discontinued its...
View Article
